ViiV’s two-monthly HIV jab bests daily oral drugs in African teenagers

Data ReadoutpositiveCabenuvatriple therapyPositive

AI Analysis

Summary

ViiV Healthcare's LATA study showed that Cabenuva, a two-monthly injectable HIV treatment, demonstrated superior efficacy compared to daily oral triple therapy in African teenagers aged 12-19 with HIV.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Cabenuva demonstrated superiority over daily oral triple therapy in African teenagers aged 12-19 with HIV

Importance:6/10

Sentiment:

0.80

HIVCabenuvaclinical trialadolescentsAfricaLATA studyinjectable therapy

Related Companies

$HR $DMAA $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 30, 2026 10:37 AM

Read Original